BAXTER INTERNATIONAL INC (BAX): what the price assumes

boothcheck covers BAXTER INTERNATIONAL INC (BAX) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/BAX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.3% sits below it).

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.3%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 13.5%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Two self-identified problems explain most of the damage: the Novum large-volume infusion pump is under a "voluntary ship and installation hold in the U.S. and Canada, which remains ongoing", and U.S. IV solutions demand has fallen because hospitals adopted "fluid conservation practices embedded with clinical practice changes".
• Operating margin is the entire verdict: about 4.4 percent on the trailing year against roughly 13.5 percent on the company's own through-cycle economics, and every valuation question here resolves into which of those two numbers is the real one.
• The balance sheet is the constraint on patience, with net debt around 7.4 billion dollars against a market value near 11.5 billion, and second-quarter results arrive on July 30, 2026.

Bull Case

One number decides this entire case. Baxter earned an operating margin of about 4.4 percent over the trailing year. On its own through-cycle economics, applied to the revenue it currently books, that margin is roughly 13.5 percent. Nothing else in the analysis matters nearly as much as which of those figures describes the business three years from now, and the useful thing about a gap that wide is that it is not a matter of opinion about the future. It is a matter of whether specific, named, currently identifiable problems get fixed.

They are named in the filing. The company has "implemented a voluntary ship and installation hold in the U.S. and Canada, which remains ongoing" on the Novum large-volume infusion pump, which is a product launch stopped in place rather than a product that failed in the market. Alongside it sits "lower demand in our IV Solutions business in the U.S. as customers continued fluid conservation practices embedded with clinical practice changes". Neither is a competitor taking share. One is a self-imposed quality hold on a new device; the other is hospitals using less saline per patient. Both compress margin through fixed-cost absorption in plants built for higher volume, which is exactly the kind of margin loss that returns when volume does.

Meanwhile management did the one thing that buys time for a fix. Baxter sold its dialysis business outright: "On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments." The proceeds went where they should have. The company repaid a billion dollars of its term loan in February 2025 and then, per the debt note, "In December 2025, we repaid the remaining $645 million outstanding under the Term Loan, at which time it was terminated." A company in trouble that retires a facility rather than extending it is signalling something about how it reads its own cash flows.

Is a 13.5 percent operating margin a fantasy for this kind of business? The cohort says no. BSX runs an 18.4 percent operating margin, STE 18.6 percent, MASI 19.9 percent, GEHC 12.6 percent, MMSI 12.2 percent, BDX 10.4 percent. Mid-teens is the ordinary destination for a diversified medical products maker with manufacturing scale, not the top of the range. What a genuinely broken one looks like is also visible in the same cohort: ICUI at 2.0 percent on revenue that shrank 10.9 percent, OMCL at 2.7 percent. Baxter's trailing margin currently sits nearer that second group than the first, and the bull case is simply that its portfolio and its plants belong in the first.

Which brings the price into it. At today's quote the market pays about 13 times what the business earns on those through-cycle economics, a multiple that sits below what a permanently shrinking profit stream would warrant. Six businesses, from infusion therapies at roughly a third of revenue through advanced surgery, patient monitoring, injectables and drug compounding, are being valued as though none of them recovers. The bull does not need the margin to reach 13.5 percent. It needs the market to stop assuming it never will.

Bear Case

Start with what sits ahead of the shareholder in line. Baxter carries net debt of roughly 7.4 billion dollars against a market value near 11.5 billion, and gross borrowings of about 9.5 billion against liquid assets of roughly 2.0 billion. The revolving facility carries "various covenants, including a maximum net leverage ratio". On the company's through-cycle earning power that leverage works out to about 5.0 times operating profit, which is heavy but survivable. On what the business actually earned over the last twelve months it is three times heavier than that, because the normalized figure the ratio uses is three times the trailing one. A balance sheet sized for the good version of the business is currently being carried by the bad version.

The trailing year was a loss, and the reason is disclosed rather than mysterious. Management wrote down its own forecast: "we recorded a $485 million goodwill impairment related to our Front Line Care reporting unit within our Healthcare Systems & Technologies segment. The reduction in value was primarily due to lower forecasted operating results, a higher discount rate and a lower terminal growth rate utilized in valuing this reporting unit". That is not an accounting artifact. It is the company's own valuation model, applied to one of its own segments, concluding that the future is worth less than it previously thought.

The revenue problem underneath has a permanent-sounding description attached to it. U.S. IV solutions demand is lower because customers "continued fluid conservation practices embedded with clinical practice changes". The operative word is embedded. Clinical practice changes are not restocking cycles; hospitals that learned to use less saline per patient do not unlearn it when supply normalizes. If that volume is structurally gone, then a meaningful share of the fixed-cost base in a manufacturing network built for the old volumes is stranded, and the through-cycle margin the bull relies on is a memory of a business with a bigger denominator.

The recent operating record does not yet contradict any of this. First-quarter 2026 sales from continuing operations were about $2.7 billion, up 3 percent as reported but down 1 percent organically, with a GAAP loss per share from continuing operations. Reported growth flattered by portfolio and currency effects, organic growth negative, and the bottom line still red: that is a business stabilizing at best, not one recovering.

The uncomfortable synthesis is that the market may already be right. The price sits below what even a steady five percent a year decline in operating profit would justify, and that reads as a bargain only if the decline is temporary. If the fluid-conservation shift is permanent, if the pump hold extends, and if the margin settles somewhere between the trailing four and a half percent and the remembered mid-teens rather than at the top of that range, then a company with this much debt has very little equity value left after the lenders are made whole. Leverage does not create the risk here. It determines who absorbs it.

Valuation

The unusual thing about this price is what it refuses to pay for. Baxter changes hands at about 13 times the operating income its own through-cycle economics would produce on current revenue, which is a multiple beneath the level a business shrinking five percent a year would warrant. The market is not debating how fast Baxter grows. It is pricing the profit stream as permanently smaller, and declining from there.

The gap that judgment rests on is worth stating with its bases attached, because the two figures are measured differently and the difference is the whole argument. Over the trailing year the operating margin was about 4.4 percent. Measured through the cycle, on the company's own historical margins applied to today's revenue, it is roughly 13.5 percent. Trailing operating income was about 0.49 billion dollars; the through-cycle figure is about three times that. Every valuation method in the exercise is really just a different way of betting on which of those two numbers is the business.

The methods split along exactly that line. The forward cash-flow approaches land essentially on today's price, because they project the recovery and then hold the trading multiple flat at the end. The book-value approaches land well beneath it, with the price sitting roughly twice the equity value carried on the balance sheet. The cash-flow-capitalization approaches, which take today's free cash flow, credit it with no growth and then subtract the borrowings, land further beneath still, with the price about 159 percent above where they center. The sales-based comparisons appear to say the shares are worth several times the current price, and they get there by applying a sector price-to-sales multiple to a company currently earning a small fraction of the sector's margin. That is a comparison that does not survive contact with the income statement, and it is worth naming rather than quietly averaging in.

Against its own sector the multiple sits in the lower half of the peer range, which is consistent with everything else here. The peer set makes the destination concrete rather than abstract: BSX at an 18.4 percent operating margin and STE at 18.6 percent describe what a healthy diversified device maker earns, while ICUI at 2.0 percent describes what one earns when its problems are structural. Baxter's trailing 4.4 percent is closer to the second, and the price has drawn the corresponding conclusion.

Solvency is where the argument stops being about multiples. Net debt of roughly 7.4 billion dollars is about 5.0 times operating profit measured through the cycle, a ratio struck on the normalized figure rather than on the depressed trailing one, and the revolving facility carries a maximum net leverage covenant. The share count has been effectively flat for four years, so there is no dilution running against the holder and no buyback working for them either. What that combination means is simple enough: the equity is a claim on the recovery of the margin, geared by the borrowings, with the timetable set by whichever of the pump hold and the fluid-conservation shift resolves first.

Catalysts

The March quarter told a mixed story that neither side of this argument can claim. Sales from continuing operations were about $2.7 billion, up 3 percent as reported and down 1 percent organically, and the company posted a GAAP loss per share from continuing operations while reaffirming its full-year 2026 outlook for flat to 1 percent sales growth on a reported basis. Management pointed to Advanced Surgery and Drug Compounding as the stronger performers, with chief executive Andrew Hider describing the quarter as in line with expectations and the work of stabilizing the business as ongoing.

Two operational items carry more weight than the quarterly headline. The ship and installation hold on the Novum large-volume pump in the United States and Canada remains in place, and every quarter it stays in place is a quarter of launch revenue that does not arrive and a quarter of manufacturing capacity that does not absorb its overhead. The second is whether U.S. IV solutions volumes stabilize at their lower level or continue to erode, since the filing attributes the decline to changes in clinical practice rather than to a temporary shift in ordering patterns.

Second-quarter results are scheduled for Thursday, July 30, 2026, with the conference call the same morning. Analyst estimates for the quarter have been moving lower rather than higher in the weeks ahead of it. The specific line worth reading first is not the earnings figure but the operating margin, because the distance between a trailing four and a half percent and a through-cycle thirteen and a half is what the entire share price is arguing about, and each quarter either narrows that distance or confirms it.

Peer Cohorts (Per Segment, With Filing Citations)

Medical Products & Therapies (reported)

• ICUI (ICU MEDICAL INC/DE)
• FY2025 10-K: …positive clinical outcomes, meeting safety, efficacy or other regulatory requirements of government agencies or notified bodies, or obtaining favorable pricing on those products. Finally, innovations may not be accepted in the marketplace quickly or at all because of, among other things, entrenched patterns of…
• FY2025 10-K: …Containers and Pour Bottle Options. Hemodynamic Monitoring Our Hemodynamic Monitoring products are designed to help clinicians get accurate real-time access to patients' hemodynamic and cardiac status with an extensive portfolio of monitoring systems and advanced sensors & catheters. Measurements provided by our…
• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …focus on products using materials of concern and demand for more sustainable products, and for products utilizing emerging technologies (such as AI), as well as changes in the ways healthcare services are delivered, such as the transition of more care from acute to non-acute settings and increased focus on chronic…
• FY2025 10-K: …the prices customers are willing to pay for those products in a particular jurisdiction. In addition, third-party payers are increasingly challenging the reimbursement models and prices charged for medical products and services. Any changes to the reimbursement landscape, or adverse decisions relating to our products…
• TFX (TELEFLEX INCORPORATED)
• FY2025 10-K: …are located in the Czech Republic, Malaysia, Mexico and the United States (the "U.S."). We are focused on achieving consistent, sustainable and profitable growth and improving our financial performance by increasing our market share and improving our operating efficiencies through: • development of new products and…
• FY2025 10-K: …rapid technological advances characterize the market in which we compete. We must continue to develop and acquire new products and technologies for our businesses to remain competitive. We believe that we compete primarily on the basis of clinical superiority and innovative features that enhance patient benefit,…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …operating segments: cardiovascular and endoscopy. For information relating to our operating segments and product categories, see Note 13 Segment Reporting and Foreign Operations to our consolidated financial statements set forth in Item 8 of this report and Management's Discussion and Analysis set forth in Item 7 of…
• FY2025 10-K: …rhythm management; interventional pulmonology; interventional nephrology; orthopedic spine surgery; interventional oncology; pain management; breast cancer surgery; outpatient access centers; intensive care; imaging; and interventional gastroenterology. According to statistics published by the World Health…
• BSX (BOSTON SCIENTIFIC CORP)
• FY2025 10-K: …costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources and evidence necessary to demonstrate value to our customers, patients, payers…
• FY2025 10-K: …seasonality, customer purchases of our medical devices have historically been lower in the first and third quarters of the year. Resources Manufacturing and Raw Materials We are focused on continuously improving our supply chain effectiveness, strengthening our manufacturing processes and increasing operational…

Healthcare Systems & Technologies (reported)

• MASI (MASIMO CORP)
• FY2025 10-K: …and worker health and safety laws; however, the risk of environmental liabilities cannot be completely eliminated. 21 Table of Contents Markets Competitive Conditions We compete in many healthcare electronic markets across the globe. These markets are highly competitive and are characterized by continual change and…
• FY2025 10-K: …noninvasive portable hemoglobin spot-check monitoring. 9 Table of Contents Patient Monitoring and Connectivity Platform Radius VSM ® is a wearable vital signs monitoring platform that includes three single-use sensors: a chest patch, a blood pressure cuff, and a finger sensor. As an on-demand, connected, continuous…
• GEHC (GE HEALTHCARE TECHNOLOGIES INC.)
• FY2025 10-K: …in hospitals and imaging centers; mobile radiography products used for bedside or other point-of-care imaging needs; and fluoroscopy products installed in hospitals for dynamic or "moving" X-ray imaging in applications like gastrointestinal examinations. We also offer a suite of AI-enabled software and applications…
• FY2025 10-K: …Together, these technologies facilitate image guided therapy across a full spectrum of interventional procedures. • Surgical Innovations products are used in the operating environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be…
• RMD (ResMed Inc.)
• FY2025 10-K: …and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and…
• FY2025 10-K: …of innovative new products by our competitors or the discovery of alternative treatments or potential cures for the conditions that our products treat could make our products noncompetitive or obsolete. Current competitors, new entrants, academics, and others currently may be developing, or may develop, new devices,…
• STE (STERIS plc)
• FY2025 10-K: …for performance assessment and resource allocation. The CEO regularly receives discrete financial information about each reportable segment and uses this information to assess performance and allocate resources. The accounting policies of the reportable segments are the same as those described in Note 1 to our…
• FY2025 10-K: …within our Healthcare segment have historically been higher in the fourth quarter of our fiscal year. However, we cannot guarantee that these patterns will persist. Backlog. We define backlog as the amount of unfilled capital equipment purchase orders at a point in time. At March 31, 2025, we had a backlog of $452.9…
• OMCL (OMCL)
• FY2025 10-K: …brand recognition, and in relationships with our suppliers and current and potential customers . • Technology Risks. We may be unable to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner. Our products and services now…
• FY2025 10-K: …to create larger healthcare delivery organizations. As market demands, government regulations, and societal pressures continue to cause the healthcare industry to evolve, it could result in further business consolidations and alliances among the industry participants with whom we engage and compete. We believe our…

Pharmaceuticals (reported)

• JNJ (Johnson & Johnson)
• FY2025 10-K: 2025, representing an increase of 10.1% as compared to the prior year. Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand. Growth was partially offset by the sales decline of INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Medicare Part D…
• FY2025 10-K: …market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company's subsidiaries may settle these types of actions and such settlements can…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …directly or indirectly, through reimbursement, payment, pricing, coverage limitations, or compulsory licensing. Political and budgetary pressures in the United States and in other countries may also heighten the scope and severity of pricing pressures on AbbVie's products for the foreseeable future. United States.…
• FY2025 10-K: …2026 to the mid 2040s, in aggregate are believed to be of material importance in the operation of AbbVie's business. The following patents, licenses and trademarks are significant: those related to risankizumab (which is sold under the trademark Skyrizi) and those related to upadacitinib (which is sold under the…
• LLY (ELI LILLY & Co)
• FY2025 10-K: …and vendors. These agreements may be breached, and we cannot be certain that we have adequate remedies. If our trade secrets or confidential information become known or are independently discovered by competitors, or if we enter into disputes over ownership of inventions, our business and results of operations could…
• FY2025 10-K: …U.S. Private Sector Dynamics In the U.S. private sector, consolidated and integrated healthcare organizations significantly affect the competitive marketplace for pharmaceuticals. Health plans, managed care organizations, pharmacy benefit managers, wholesalers, pharmacies, and other supply chain entities have…
• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …consolidation and integration of pharmacy chains, wholesalers and pharmacy benefit managers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us. Third-party royalties represent a significant percentage of our pretax income and operating cash flow. We have entered into several…
• FY2025 10-K: …end of regulatory exclusivity or the COM patent expiration for the respective products and PTR if granted. In situations where there is only regulatory exclusivity without patent protection, a competitor could seek regulatory approval by submitting its own clinical study data to obtain marketing approval prior to the…
• PFE (Pfizer Inc.)
• FY2025 10-K: …us for the development of technologies and processes or greater experience in particular therapeutic areas, and technological innovation and/or consolidation among certain pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them…
• FY2025 10-K: …Payors may give preference to generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. Some states…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.